

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 July 2023 (06.07.2023)



(10) International Publication Number
WO 2023/129892 A1

(51) International Patent Classification:

A61K 9/12 (2006.01) A61K 9/00 (2006.01)
A61K 45/06 (2006.01) A61K 47/10 (2017.01)
A61K 47/08 (2006.01)

(21) International Application Number:

PCT/US2022/082350

(22) International Filing Date:

23 December 2022 (23.12.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/294,178 28 December 2021 (28.12.2021) US
63/371,967 19 August 2022 (19.08.2022) US

(71) Applicant: **ARCUTIS BIOTHERAPEUTICS, INC.**
[US/US]; 3027 Townsgate Road, #300, Westlake Village,
California 91361 (US).

(72) Inventor: **OSBORNE, David W.**; 4215 Creekside Court,
Fort Collins, Colorado 80525 (US).

(74) Agent: **KITTS, Monica Chin et al.**; Rothwell, Figg, Ernst
& Manbeck, P.C., 901 New York Avenue, Suite 900 East,
Washington, District of Columbia 20001 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(54) Title: TOPICAL AEROSOL FOAMS

Figure 1

Fig. 1A Acceptable Expanding Foam





Fig. 1B Acceptable Quick-Breaking Foam





Fig. 1C Acceptable Soft Foam




Fig. 1D Acceptable Sinter Foam






Fig. 1E Unacceptable Foam



(57) Abstract: The present invention is directed to an aerosol foam composition comprising an active pharmaceutical ingredient (API) with low water solubility an emulsifier blend containing cetearyl alcohol, dicetyl phosphate, and ceteareth-10 phosphate and a hydrocarbon propellant. The aerosol foam composition is preferably an oil in water emulsion. The propellant is a mixture of liquefied hydrocarbon gases preferably a propane/isobutane/butane blend. The hydrocarbon propellant results in an aerosol foam which is stable, has consistent physical properties, excellent aesthetics, and no discernable API degradation after long term or accelerated storage conditions.

WO 2023/129892 A1

[Continued on next page]

Published:

— with international search report (Art. 21(3))